Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Osteoarthritis, Hip: full-pipeline trial registry
7 of 21 indexed Osteoarthritis, Hip trials are currently recruiting.
Corpus placement: #797 of 28,707 conditions by registered trial count.
21 US clinical trials · 7 currently recruiting · #797 of 28,707 conditions by registered trial count
Osteoarthritis, Hip: 21 US clinical trials tracked, 7 recruiting.
Osteoarthritis, Hip is the subject of 21 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Regeneron Pharmaceuticals, running 4 of these trials.
Enrollment posture brief
Registry condition osteoarthritis-hip
OPEN 7 | RECR 33% | LATE 3 | EARLY 4 | RANK #797 | SPON 4
Volume-matched condition peers
Nearest open-share peer: Adherence, Treatment (33% recruiting · 6 trials)
Osteoarthritis, Hip lists 7 open slots (33% of 21 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Osteoarthritis, Hip on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Osteoarthritis, Hip is recruiting below its size-band peers.
7 of 21 indexed trials (33.3%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Osteoarthritis, Hip research.
Regeneron Pharmaceuticals accounts for 4 of 21 trials (19%). 16 distinct sponsors appear on at least one study for this condition label.
-
Typical Osteoarthritis, Hip enrolment sits around 120 participants.
Median target enrolment is 120 among the 21 trials that report a genuine target (sentinel values excluded). 7 of those (33.3%) plan for fewer than 100 participants.
-
Osteoarthritis, Hip research is mostly interventional.
18 interventional and 3 observational studies make up this index (85.7% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
21 total, page 1 of 1
Outcomes of Low-Impact Exercise Program for People With Ankle, Knee, and/or Hip Pain
University of Missouri-Columbia
NCT03711773
G7 Acetabular System With Vivacit-E or Longevity Liner PMCF Study
Zimmer Biomet
NCT04754087
Safety and Effectiveness of the HIT Reverse HRS
Hip Innovation Technology
NCT05357378
Perfusion MRI-targeted Joint Embolization for Chronic Musculoskeletal Pain of the Shoulder, Hip and Knee
Palo Alto Veterans Institute for Research
NCT05700682
Adipose-Derived Biocellular Regenerative Therapy for Osteoarthritis
Healeon Medical
NCT04238143
Non-invasive Evaluation of Upper and Lower Body Function With Showmotion
University of Colorado, Denver
NCT04137835
Early Feasibility Study of Cartilage Defect Repair
Cytex Therapeutics
NCT06823089
Avenir Complete Post-Market Clinical Follow-Up Study
Zimmer Biomet
NCT04731077
Arthroscopic Labral Repair Versus Physical Therapy for Tears of the Acetabular Labrum
Massachusetts General Hospital
NCT03909178
Autologous Culture Expanded Adipose Derived MSCs for Treatment of Painful Hip OA
Mayo Clinic
NCT03608579
A Prospective Multicenter Longitudinal Cohort Study of the Mymobility Platform
Zimmer Biomet
NCT03737149
A Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Naproxen for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Regeneron Pharmaceuticals
NCT03161093
Study to Determine the Safety and the Efficacy of Fasinumab Compared to Placebo and Nonsteroidal Anti-inflammatory Drugs (NSAIDs) for Treatment of Adults With Pain From Osteoarthritis of the Knee or Hip
Regeneron Pharmaceuticals
NCT03304379
Efficacy and Safety Study of Lumiracoxib in Patients With Primary Hip Osteoarthritis
Novartis
NCT00154219
Understanding the Differences in the Management of Patients With Arthritis of the Knee or Hip
US Department of Veterans Affairs
NCT00105677
Study to Evaluate the Effects of Fasinumab on Peripheral Nerve Function in Patients With Pain Due to Osteoarthritis of the Hip or Knee
Regeneron Pharmaceuticals
NCT03691974
To Assess the Patients' Ability to Self-Administer Fasinumab
Regeneron Pharmaceuticals
NCT03491904
Effectiveness of Healthy Habits for Hospitalized Older Adults to Optimize Rehabilitation
Baylor College of Medicine
NCT04269239
OA Clinic-Community CARE Model
University of North Carolina, Chapel Hill
NCT05349500
Acetabular Shell Positioning Using Patient Specific Instruments
The Cleveland Clinic
NCT01791738
Dual Energy X-ray Absorptiometry (DXA) Comparison Hip Resurfacing Versus Total Hip Arthroplasty (THA)
Spokane Joint Replacement Center
NCT01359527
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 1 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Osteoarthritis, Hip records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Osteoarthritis, Hip trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Osteoarthritis, Hip page
21 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Osteoarthritis, Hip trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Regeneron Pharmaceuticals sponsors the most Osteoarthritis, Hip trials on record, review their full trial history before evaluating a specific study. See Regeneron Pharmaceuticals's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Osteoarthritis, Hip condition card totals 21 registered trials; most-linked intervention Fasinumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.